RxDoctor Payments Data

Emad Nukta, MD

Interventional Cardiology · Fairview Park, OHNPI 1922051937

Payments from drug & device makers

$24,511in general payments, 2019–2025

Across 352 payments — averaging $69.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$8K
  • Abbott$7K
  • Boston Scientific$2K
  • Abiomed$1K
  • Novartis$1K
  • Shockwave Medical, Inc$798
  • plus $5K from 40 others

What the payments were for

  • Grants$550%
  • Travel & lodging$2,47319%
  • Food & beverage$10,40880%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,511 in reported general payments places this provider in the 65th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$131,707
Medicare patients
931
Services billed
1,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$363,305
XareltoRivaroxaban67$88,481
BrilintaTicagrelor80$85,987
EntrestoSacubitril/Valsartan55$73,124
OzempicSemaglutide48$67,241
JardianceEmpagliflozin39$60,637
Repatha SureclickEvolocumab77$51,196
Atorvastatin Calcium1,231$13,576
Praluent PenAlirocumab17$12,418
Metoprolol Succinate604$7,610
Ezetimibe200$6,441
Rosuvastatin Calcium389$5,160
Metoprolol Tartrate642$4,061
Ranolazine ErRanolazine20$3,698
ClopidogrelClopidogrel Bisulfate302$3,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$406$363,305285 claims
Johnson & JohnsonXarelto$598$88,48167 claims
AstraZenecaBrilinta$220$85,98780 claims
NovartisEntresto$1,054$73,12455 claims
Novo NordiskOzempic$464$67,24148 claims
Boehringer IngelheimJardiance$262$60,63739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Fairview Park

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →